Grifols, S.A.

NASDAQ:GRFS

Drug Manufacturers - General

Healthcare
$8.47 +0.34%

+$0.03 today

Market cap
$7.17B
Beta
1.17
P/E (TTM)
14.7
EPS (TTM)
$0.61
Dividend yield
1.67%
52W Low $7.26High $11.14

Volume 0.59M

Average 0.69M

GRFS Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Grifols, S.A.NASDAQ: GRFS

Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares declines year over year

Q2 FY2026 weighted avg shares of 680.58M shares fell 1.2% year over year, behind the -0.2% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +0.0% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -1.2% toward the trailing-twelve-month pace of -0.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
680.58M+0.0% QoQ
Last fiscal yearDec 2025
680.58M+0.1% YoY
LTMJun 2026
680.56M-0.2% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.2%——
1 year+0.1%——
3-year CAGR+0.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
680.58M EUR
Year-over-year change
+0.1%
4-year CAGR
-0.0%

Weighted Avg Shares vs competitors

How GRFS compares with its peers on the latest reported figures

  • GRFS's LTM Jun 2026 weighted avg shares of 680.56M shares is the 2nd highest of the 9 companies compared; the peer median is 151.08M shares.
  • Its year-over-year change of -0.2% is the 4th highest of 9, against a peer median of -0.6%.
  • Over three fiscal years its annual growth of +0.0% compares with a peer median of -0.2%.
GRFS Competitors Peer median
Weighted Avg Shares for GRFS and competitors
Company Period LTM YoY 3-year CAGR
ABTAbbott LaboratoriesLTM Sep 20261.74B +0.1%-0.1%
GRFSGrifols, S.A.LTM Jun 2026680.56M -0.2%+0.0%
BDXBecton, Dickinson and CompanyLTM Sep 2026278.36M -3.4%-0.9%
ADMAADMA Biologics, Inc.LTM Jun 2026235.22M -1.0%+6.4%
TECHBio-Techne CorporationLTM Sep 2026156.12M -0.3%-0.3%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026146.04M +2.7%+3.3%
QDELQuidelOrtho CorporationLTM Mar 202667.93M +1.0%+6.1%
HAEHaemonetics CorporationLTM Jun 202646.49M -6.3%-2.4%
BIOBio-Rad Laboratories, Inc.LTM Jun 202626.9M -3.2%-2.9%
Peer median (excluding GRFS) 151.08M-0.6%-0.2%

Competitors are the stored peer set for GRFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.93B6.06B6.59B7.21B7.23B
Cost of Revenue2.97B3.85B4.11B4.42B4.65B
Gross Profit1.96B2.21B2.48B2.79B2.58B
Gross Margin39.8%36.5%37.7%38.7%35.7%
Research & Development354.88M361.14M395.28M384.04M358.28M
Selling, General & Admin1.06B1.11B1.27B1.14B1.02B
Operating Expenses1.37B1.43B1.7B1.6B1.39B
Depreciation & Amortization359.77M410.98M446.42M437.9M432.24M
EBITDA944.03M1.19B1.17B1.48B1.62B
EBITDA Margin19.1%19.7%17.7%20.6%22.5%
Operating Income595.06M782.44M782.32M1.19B1.19B
Operating Margin12.1%12.9%11.9%16.5%16.4%
Interest Income11.55M33.86M62.43M48.05M32.66M
Interest Expense233.81M444.54M516.06M773.16M600.33M
Other Income / Expenses(244.61M)(444.42M)(575.3M)(748.02M)(596.49M)
Income Before Tax350.45M338.01M207.02M444M590.73M
Pre-Tax Margin7.1%5.6%3.1%6.2%8.2%
Income Tax Expense85.13M90.11M43.35M231.19M110.46M
Net Income188.73M185.04M42.32M156.92M386.13M
Net Margin3.8%3.1%0.6%2.2%5.3%
EPS (Basic)0.270.310.090.230.57
EPS (Diluted)0.270.310.090.230.57
Weighted Avg Shares681.56M679.81M679.76M680.02M680.58M
Weighted Avg Shares (Diluted)681.56M679.81M679.76M680.02M680.58M

Grifols, S.A.

NASDAQ:GRFS

Intrinsic Alpha fair value

Locked

Current Price

$8.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.